Coming soon is a premium service offered in collaboration with Investars YOU for full access to a global database that includes over 1,000 stocks / ETFs (exchange-traded funds) which are organized and managed within my 24 ProActive HavRx Indexes. This service will allow investors to create custom portfolios and generate investment ideas based on their personal preferences, beliefs, and opinions through specialized stock indexes that are organized and targeted toward a wide variety of market themes and trends with initial pricing of $60 per year for a limited time and standard pricing of $99 per year for the service.

 

The HavRx Pet Care / Animal Farma Index is passively managed and tracks the performance of companies with market caps below $5 billion at the time of inclusion that are active in the following business segments: animal breeding, animal pharming, veterinary stem cells, veterinary services, pet retailers, animal feeds / nutrition, and veterinary diagnostics.

The HavRx Diabetes Care Index is actively managed and tracks the performance of companies which derive the majority of revenue from diabetes care products, have double-digit market share for any type of diabetes care market, and / or have a diabetes care product in development.

The HavRx Cosmetic / Restorative Medicine Index is actively managed and tracks the performance of companies that derive over 50% of revenue from any of the following activities: (1) prescription skin care therapeutics; (2) medical devices, products, services, OR equipment for procedures which are intended to enhance appearance; (3) medical devices, products, services, OR equipment for use as joint replacements, tissue repair agents, tissue reconstruction agents, surgical adhesives, and cardiovascular procedures; and (4) regenerative medicine products, services, and/or an active clinical pipeline which seeks to restore or repair the functionality of lost or damaged organ, tissue, cellular, and genetic material.

The actively managed HavRx Regulatory Catalyst Index tracks the performance of select healthcare companies with pending new drug, biological agent, medical device, and diagnostic product decisions at the FDA.

The HavRx Life Science Leaders Index is passively managed and tracks the performance of companies with market caps of at least $20 billion at the time of index inception that derive the majority of revenue from any type of healthcare product or service, medical device / diagnostic, drug / biological agent, and agri-biotech (crop science and seeds).

The HavRx Natural Health Index is actively managed and tracks the performance of companies that manufacture, distribute, or sell any type of non-prescription, over-the-counter (OTC) vitamin / mineral product, herbal / natural remedy, nutraceutical, functional / organic food, or other type of health supplement / enhancement product.

The HavRx Immune Therapy / Vaccines Index is actively managed and tracks the performance of companies with market caps below $20 billion at the time of index inclusion which are developing or commercializing any type of cancer immunotherapy or therapeutic / preventative vaccine product that is designed to stimulate the immune system for the eradication, combination treatment, or prevention of cancer. In addition, the index will track companies which are developing or commercializing any type of vaccine product or vaccine adjuvant for all types of infectious disease such as influenza (flu) and bio-defense applications.

The actively managed HavRx Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index constituents reflect a cross-section of emerging cancer companies with market caps below $500 million at the time of index inclusion, encompassing the following categories: (1) diagnostics (molecular diagnostics and device-based diagnostics), (2) lab services (personalized medicine applications to guide and track the effectiveness of cancer treatments), (3) drug discovery (screening and modifying compounds to achieve anti-cancer effects during the early stages of preclinical and Phase 1 clinical studies), (4) immunotherapy (a.k.a. cancer vaccines which are designed to stimulate the immune system to eradicate cancer), and (5) commercial or late-stage (Phase 2-3) clinical development therapeutics, devices, or diagnostics intended for use by cancer patients.

The HavRx Global Generic Drug Index is passively managed and tracks the performance of companies which meet any of the following three requirements: (1) Derive either $500 million (USD) OR more than 50% of trailing 12-month revenue from the manufacture and sale of any type of generic (off-patent) prescription or over-the-counter (OTC) drug product intended for use by humans, including contract manufacturing services, active pharmaceutical ingredient (API) suppliers, and intermediate product suppliers for drug products and biological agents; (2) Have one or more compound(s) in active clinical development OR have a pending ANDA with the FDA for a generic drug candidate; (3) Receive FDA approval for an ANDA within the past 12 months. The index excludes all companies that derive over 50% of trailing 12-month revenue from the sale of patent-protected or legacy brand prescription or OTC drug products.

The HavRx Global Health Information Technology (Health IT) Index is passively managed and tracks the performance of companies with market caps below $10 billion that derive over either $50 million or 50% of their trailing 12-month revenue from products and services for the following activities: (1) electronic transmission, storage, and processing of prescriptions; (2) secure e-mail transmission for healthcare facilities; (3) electronic transmission, storage, and processing of medical imaging and diagnostic information; (4) electronic storage and systems for administrative functions of healthcare facilities and medical records; (5) electronic transmission, storage, and systems for healthcare market data and clinical trial data; (6) electronic systems, devices, and services for remote, real-time monitoring of patient health parameters; (7) medical transcription services, products, and systems for conversion into electronic medical records.

The HavRx Global Hospital Index is passively managed and tracks the performance of companies which derive the majority of their revenue from the following activities: hospitals, inpatient rehabilitation facilities, dialysis facilities, hospice providers, inpatient behavioral healthcare facilities, and ambulatory surgery centers. The revenue requirement for this index excludes the following activities: home healthcare, outpatient medical services, and senior living centers.

The HavRx Global Stem Cells Index is actively managed and tracks the performance of regenerative medicine companies that derive the majority of their revenue or have compound(s) in active pre-clinical or clinical development which are designed to restore, replace, repair, or enhance the functionality or appearance of tissue and organ systems, including all types of embryonic and adult stem cell therapeutics. In addition, all types of products and services for stem cell banking are included in this index.

The HavRx Health Benefit Providers Index is passively managed and tracks the performance of retail pharmacies, pharmacy benefit managers, managed care companies, health insurers, hospital pharmacy operators, workers compensation insurers, and specialty health benefit providers.

The HavRx Global Crop Science Index is passively managed and tracks the performance of companies that derive the majority of their revenue from any of the following agricultural business activities: fertilizers, potash, farming, seeds, insecticides, herbicides, and other ag-related chemicals.

The HavRx Healthcare ETF Index is passively managed and tracks the performance of healthcare sector exchange-traded funds (ETFs).

 

The ProActive Global Clean-Tech Index is actively managed and tracks the performance of companies which either generate carbon credits through their business operations, are involved with the trading of carbon credits, or reduce carbon emissions through their business activities. In addition, the index may include companies that supply renewable energy products, services, and raw materials / resources for applications such as waste-to-energy, landfill / methane gas collection, clean energy / bio-fuels, smart electric grid / power management, energy efficiency, water supply infrastructure, and all other forms of alternative energy such as wind, solar, battery, and hydropower.

The ProActive Global Railroad Industry Index is passively managed and tracks the performance of companies that derive either more than 50% OR $100 million of trailing 12-month revenue from any of the following activities: (1) passenger or freight rail transport services; (2) railcar and locomotive leasing; (3) railcar and locomotive fleet management; (4) rail infrastructure, railcar, locomotive, and railcar/locomotive component parts manufacturing; (5) railcar, locomotive, and component parts repair or refurbishment. 

The ProActive Global Tobacco Industry Index is passively managed and tracks the performance of companies which derive over 50% of their revenue from the distribution or manufacturing of any type of tobacco product (e.g. cigarettes, cigars, chewing tobacco), tobacco supplies (e.g. wrapping papers, tobacco leafs, filters), and electronic cigarettes (e-cigarettes).

The ProActive Global Telecom Services Hi-Dividend Index is passively managed and tracks the performance of companies with market caps over $1 billion at the time of inclusion that meet the following requirements: (1) All such companies must derive at least 50% of their trailing 12-month revenue from any types of voice and data telecom services such as fixed line communications, wireless communications, and internet access provider services and (2) All such companies must have a trailing 12-month dividend yield of at least 1.5%.

The ProActive Nation Cap Leaders Index is passively managed and tracks the performance of companies that are market cap leaders from each nation at the time of index inception (at least $5 billion) and including developed, emerging, and frontier markets.

The ProActive Highly Defensive Index is actively managed and tracks the performance of companies based in the Americas, Canada, and Europe which are market cap leaders (at least $5 billion market caps) from the following industry groups: (A) Mass Merchant Discount Retailer; (B) Consumer Staples; (C) Telecom Services; (D) At-Home Services:  Cable TV/Internet Provider, Internet Portal/Search Provider; (E) Utilities; (F) Fast Food; (G) Commodities; (H) Healthcare; (I) Aerospace (Non-Commercial) & Defense; (J) Energy.

The ProActive Global Trucking / Logistics Index is passively managed and tracks the performance of companies with market caps over $100 million at the time of inclusion that derive at least 50% of trailing 12-month revenue from any of the following activities: logistics and management support services for all types of transportation companies; all types of land-based, roadway freight forwarding freight transportation services; mail package delivery, transportation, and logistics services; and logistics management support services for roadway transportation companies.

The ProActive Global Metals / Mining Index is passively managed and tracks the top-rated companies with market caps over $1 billion upon inception that derive over 50% of revenue from the exploration, mining, extraction, processing, and sale of all types of precious metals, minerals, and industrial metals. The top rated companies are chosen based on their trailing 12-month stock price performance, market cap weighting, and net income weighting.

The ProActive Global Air Transport Index is passively managed and tracks the performance of companies that derive the majority of their revenue from passenger airline services, helicopter transport services, and air freight transport activities.